ISPOR Europe Event 2024 at Barcelona, Spain

ISPOR Europe 2024

Following on from our attendance at ISPOR Europe in Barcelona, Spain in November, we are delighted to share our report.

Our Report

Issue Panels

We are delighted to have run two issue panels at ISPOR Europe 2024, Barcelona. The details of each session can be found below.

 

Is It Time for More Non-Profits to Lead Reimbursement and Commercialisation of Gene Therapies to Promote Affordable and Sustainable Access?

Following withdrawals of gene therapies by for-profit manufacturers, Kate will moderate an issue panel discussing whether non-profit-led gene therapy development and commercialisation could promote more affordable and sustainable access, exploring commercial challenges, patient perspectives and resource requirements needed to navigate the upcoming mandatory EU JCA.

  • Date: Tuesday, 19 November
  • Session Time: 13:45–14:45
Panel image of Kate Hanman

 

Take My Word for It: Can Patient-Centric Social Listening Enrich RWE?

Siddharth will lead a discussion exploring social media listening (SML) as a medium of real-world data, the role of AI in SML analysis, acceptable use cases and evidence standards for use of SML in HTA.

  • Date: Wednesday, 20 November
  • Session Time: 10:00–11:00

 

Panel image of Siddharth Ramanan

Our Research Posters

We were delighted to present 16 research posters at ISPOR Europe 2024, Barcelona. The titles of our research are listed below, alongside the poster session dates and times.

Joint Clinical Assessment

Monday, 18 November

HTA102: Are EU JCA Evidence Requirements Achievable? Insights From a Retrospective Evidence Analysis Study for Rare and Non-Rare EU Treatment Landscapes

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

 

Tuesday, 19 November

PT25: Potential for Standardization in Economic Assessment Across HTA Bodies: A Case Study in First-Line Treatments of Non-Small Cell Lung Cancer

This poster has been selected for a poster tour given the particularly high impact nature of the research conducted.

  • Poster Session: 10:30–13:30
  • Discussion Hour: 11:30–12:15

HTA216: Navigating Prospective PICO Consolidation in Oncology: Insights From Retrospective Simulations for Crowded and Non-Crowded EU Treatment Landscapes

  • Poster Session: 10:30–13:30
  • Discussion Hour: 12:30–13:30

HTA Processes

Monday, 18 November

HTA24: What Key Areas of Clinical and Economic Uncertainty Have Scottish Medicines Consortium (SMC) Identified in Ultra-Orphan Initial Assessments to Date?

  • Poster Session: 10:30–13:30
  • Discussion Hour: 12:30–13:30

HTA85: Company-Led Submissions to the Agency for Care Effectiveness (ACE) in Singapore: What Drives Patient Access?

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

HTA90: The NICE Diagnostics Assessment Programme: Does Assessment Lead to Approval?

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

Evidence Development

Monday, 18 November

SA4: From Approval to Publication: Study Types and Timeframes using the UK Clinical Practice Research Datalink

  • Poster Session: 10:30–13:30
  • Discussion Hour: 12:30–13:30

 

Tuesday, 19 November

MSR107: Developing and Testing AI-Generated PICOs Summaries to Aid in Literature Reviews

  • Poster Session: 10:30–13:30
  • Discussion Hour: 12:30–13:30

MSR154: Comparison of Methods to Estimate Total Person-Time at Risk for Synthesis Studies of Incidence Rates in Observational Data

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

Economic Evaluation

Monday, 18 November

HTA110: Acceptance of Cure Assumptions in NICE Oncology Technology Appraisals: Remission Impossible?

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00-19:00

 

Tuesday, 19 November

EE354: An Exploratory Cost-Effectiveness Analysis of Cancer Vaccines in Combination With Current Immune Checkpoint Inhibitors Vs Immune Checkpoint Inhibitor Monotherapy: A Case Study for V940 in High-Risk Stage 3 Melanoma in the US

  • Poster Session: 10:30–13:30
  • Discussion Hour: 12:30–13:30

HTA251: Investigating the Quantitative Effect of Integrating Environmental Impacts Into Economic Evaluations: To What Extent Could Environmental Sustainability Influence Decision Making in Health Technology Assessment?

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

Patient-Centred Research

Monday, 18 November

PCR61: Capturing the Real-World Patient Perspective in HTA: Expert Patient Insights Lead to Robust Healthcare Cost and Resource Use Inputs for Cost-Effectiveness Model in Spinal Muscular Atrophy

  • Poster Session: 10:30–13:30
  • Discussion Hour: 12:30–13:30

HTA131: Opportunities for Patient Involvement in HTA in the Philippines: Lessons From Guidelines in Europe, North America, and the Asia-Pacific

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

Health Policy

Monday, 18 November

SA25: Shaping Health Policy and Clinical Practice: A Critical Evaluation of Literature Review Methods in the Evidence Base

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00

SA35: How Do Healthcare Professionals Perceive Delphi Panels and Use Study Outcomes?

  • Poster Session: 16:00–19:00
  • Discussion Hour: 18:00–19:00
Loading
Cookies Overview
Costello Medical

Our website uses cookies to distinguish you from other users. This helps us to provide you with a good experience when you browse our website and also allows us to improve our site. Cookies are files saved on your phone, tablet or computer generated when you visit a website and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

You can select to accept or reject non-essential cookies using the toggle below. For full details of the cookies we use, please see our Cookies Policy and Privacy Notice.

Non-essential Cookies

We use these to collect information on how our users engage with our website so that we can improve the experience of the website for our users. For example, we collect information about which of our pages are most frequently visited, and by which types of users.